消息面，上周七部门联合印发《医药工业数智化转型实施方案（2025—2030 年）》，提出以全产业链 协调发展为主线，以数智化改造为主攻方向推进医药工业高端化、智能化、绿色化、融合化发展。 政策目标涵盖了医药研发、生产、流通、监管等全产业链环节，强调通过数智技术提升医药全产业链竞 争力和全生命周期质量管理水平，体现了从整体上推动医药工业升级的理念，是突破国内医药工业研发 效率低、成本高、生产智能化水平不足、供应链协同弱等问题的核心路径。数智技术与医药研发深度融 合，有望动国产创新药、高端医疗器械发展。 医药见底复苏？今年来行情持续活跃，医疗ETF（159828）涨1.3%。 另外美国临床肿瘤学会（ASCO）年会作为全球规模最大、最具权威性的临床肿瘤学会议之一，将于5 月30日-6月3日在芝加哥举行。国内多个药企即将在ASCO 2025上披露最新临床数据，多个国产创新药 品种有望做口头报告，或催化创新药板块行情。 医药行业已经历了超过四年的调整期，目前创新药械收入和利润正逐步兑现，板块反腐、关税扰动逐步 减弱，机构持仓水平降至历史低位。医药作为高弹性行业有望在2025年跑赢市场。 注：指数/基金短期涨跌幅及历史表 ...

本报告导读： 2025Q1 市场交投活跃提振经纪与投资业务。公司大力推进AI 在业务场景的落地应用，有望率先显现数 智化成效。 投资要点： 2024 年投行业务同比下滑拖累业绩，2025Q1 市场交投活跃提振经纪与投资业务。1）2024 年受市场环 境影响，投行业务同比-32.04%至9.1 亿元，贡献了调整后营收（营业收入-其他业务支出）增量 的-652.66%，拖累业绩。此外，投资业务净收入同比+7.19%至18.1 亿元，占调整后营收增量的 184.56%，支持业绩；2）2025Q1 市场交投活跃度同比大幅提升，公司经纪业务同比+58.26%至6.08 亿 元，占调整后营收增量的55.58%，是业绩大幅增长的主因。同时，投资业务净收入同比+48.5%至6.42 亿元，贡献了调整后营收增量的52.06%。基数原因外，Q1 金融资产规模环比提升64.65%，增厚了投资 收益。 维持"增持" 评级，略上调目标价至9.42元。公司2024年营收/归母净利润66.64/16.70 亿元，同 比-0.98%/-2.80%；加权平均ROE 同比-0.35pct 至5.04%。2025Q1 年营收/归母净利润18.85 ...

Core Viewpoint - Zhang Xiaoqin achieved revenue and profit growth in Q1 2025, demonstrating strong operational resilience and market adaptability [1][3]. Group 1: Financial Performance - The company reported a revenue of 225 million yuan, a year-on-year increase of 5.65% [1]. - Net profit attributable to shareholders reached 12.9867 million yuan, up 69.49% year-on-year [1]. - The net profit after deducting non-recurring items was 12.7348 million yuan, reflecting an 85.47% year-on-year growth [1]. Group 2: Product Innovation and Standards - The company focused on high-end and diversified product matrices in the knife and scissors sector, launching successful series such as Black Warrior and Ancient Rhythm [2]. - Several product standards received the "Leader" title from the China Standardization Research Institute, enhancing the company's industry influence [2]. - The company's digital economy project was recognized as an excellent case in Zhejiang Province, marking progress in smart manufacturing and digital transformation [2]. Group 3: Channel Optimization - The company actively engaged in both live e-commerce and traditional e-commerce, adapting to consumer demands across different platforms [3]. - It established a live streaming matrix and collaborated with key influencers to enhance brand influence and user engagement [3]. - The company systematically advanced content creation and live streaming strategies in traditional e-commerce, solidifying its online business foundation [3].

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 迪安诊断(300244) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 特检占比持续提升，数智化提升运营 能力 夯实产品能力，ICL 实现 17%稳健增长 特检业务快速增长，自产产品拿证加 速 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 业绩短期承压，检验业务呈现高质量发展 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary] 2024 年年报，2024 年实现营业收入 121.96 亿元（yoy- 9.04%），归母 ...

Core Insights - The 26th China Environmental Expo was held in Shanghai, featuring 2,279 companies from 22 countries and regions, covering an exhibition area of 187,000 square meters [1] - Sinochem Environmental showcased its eight subsidiaries, emphasizing their core competencies in innovative technologies, products, and services across various environmental sectors [1][4] Group 1: Water Management - Sinochem Environmental Water (Jiangsu) Co., Ltd. highlighted the "Sinochem Environmental Yangzhou Huayu" project, which provides wastewater treatment services for over 40 enterprises in the Yangzhou Chemical Park, with a treatment capacity of 20,000 tons per day and 100% compliance with discharge standards [3] - The project incorporates photovoltaic green electricity for enhanced management efficiency and aims to create a smart water management system for digital transformation [3] Group 2: Soil and Resource Management - Sinochem Environmental Remediation (Shandong) Co., Ltd. focuses on sustainable solutions for saline-alkali land, integrating appropriate engineering techniques based on regional characteristics and land use [3] - The company aims to enhance the ecological value of saline-alkali land and achieve sustainable development through a comprehensive improvement technology system [3] Group 3: Waste Management and Recycling - Sinochem Environmental Technology Engineering Co., Ltd. presented initiatives for solid waste management reform, emphasizing source reduction and resource utilization [4] - The company showcased its capabilities in "green chemistry," "element cycling," "water cycling," and "soil health," providing innovative technologies, products, and services [4] Group 4: Innovation and Collaboration - Hangzhou Water Treatment Technology Research and Development Center Co., Ltd. introduced a selective nanofiltration membrane product that efficiently separates high-value metal ions from lithium brine, contributing to the low-carbon and green transformation of the membrane industry [4] - Sinochem Innovation (Beijing) Research Institute Co., Ltd. focused on technological innovation in water cycling, element cycling, and agricultural cycles, offering environmental consulting and training services [4] Group 5: Industry Engagement - The Sinochem Environmental booth attracted numerous leaders from the Chinese environmental industry, as well as international visitors from countries like Germany and Japan, fostering discussions on cutting-edge technologies and innovative solutions [5] Group 6: Future Commitment - Sinochem Environmental is committed to fulfilling its corporate mission, enhancing core competitiveness, and promoting green and low-carbon development to contribute to the construction of a beautiful China [7]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 迪安诊断(300244) 投资评级 [Table_Title] 业绩短期承压，检验业务呈现高质量发展 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary] 2024 年年报，2024 年实现营业收入 121.96 亿元（yoy- 9.04%），归母净利润-3.57 亿元（yoy-216.20%），扣非归母净利润-3.80 亿元（yoy-228.96%），经营活动产生的现金流量净额 12.07 亿元（yoy- 37.16%）。其中 2024Q4 实现营业收入 29.38 亿元（yoy-5.71%），归母净 利润-4.88 亿元（yoy-118.49%）。 点评： 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.c ...

Core Viewpoints - The report highlights a mixed performance in the A-share market, with the Shanghai Composite Index down by 0.07% and the Shenzhen Component Index and ChiNext Index up by 0.39% and 0.59% respectively, indicating a divergence in market sentiment [1] - The report notes that the Ministry of Commerce and other departments have optimized the exit tax refund policy to stimulate inbound consumption, lowering the minimum refund threshold from 500 yuan to 200 yuan and increasing the cash refund limit from 10,000 yuan to 20,000 yuan [2] - The Central Political Bureau emphasized the importance of self-reliance and application-oriented development in artificial intelligence, aiming for a healthy and orderly advancement of AI technology [2] Market Performance - The report provides a summary of domestic market performance, with the Shanghai Composite Index closing at 3,295.06 points, down 0.07%, while the Shenzhen Component Index and ChiNext Index saw increases of 0.39% and 0.59% respectively [4] - Internationally, major indices such as the Dow Jones and S&P 500 saw slight increases, with the Dow up 0.05% and the S&P 500 up 0.74% [4] Industry Insights - The report discusses the ongoing optimization of policies to stabilize the consumption sector, with a focus on increasing income for low- and middle-income groups and promoting service consumption [7] - The Central Political Bureau's meeting on April 25 highlighted the establishment of new policy financial tools to support consumption and stabilize foreign trade, indicating a proactive approach to economic management [6][7] - The report emphasizes the potential for growth in the gaming industry, with the approval of multiple game titles, including Tencent's "Path of Exile: Ascendancy," reflecting a normalization in the issuance of game licenses [15] Investment Recommendations - The report suggests focusing on sectors that will benefit from policy support, including tourism, duty-free, hotel, and restaurant industries, as well as domestic beauty brands that are gaining market share [8] - In the real estate sector, the report indicates that the market is stabilizing, with expectations for continued policy support to enhance housing consumption [11][12] - The report highlights the importance of the AI and pharmaceutical sectors, recommending attention to AI drug development and smart healthcare supply chains as key growth areas [19]

[Table_Rating] 增持（维持） [◼Table_Summary] 主要观点 [行业Table_Industry] : 医药生物 日期: shzqdatemark 2025年04月27日 | [Table_Author] 分析师: | 张林晚 | | --- | --- | | Tel: | 021-53686155 | | E-mail: | zhanglinwan@shzq.com | | SAC 编号: | S0870523010001 | [Table_QuotePic] 最近一年行业指数与沪深 300 比较 -17% -12% -8% -3% 2% 7% 11% 16% 21% 04/24 07/24 09/24 11/24 02/25 04/25 医药生物 沪深300 [Table_ReportInfo] 相关报告： 《国产替代有望加速，关注血制品投资机 会》 ——2025 年 04 月 20 日 《《促进健康消费专项行动方案》发布， 关注消费医疗板块机会》 ——2025 年 04 月 13 日 《多家创新药企迎业绩收获期，关注结构 性机会》 医药工业数智化转型方案印发。近日，工业和信息 ...

Group 1 - The Hang Seng Medical Index ETF experienced a turnover of 8.47% during the trading session, with a transaction volume of 21.38 million yuan [3] - The ETF's scale increased by 18.48 million yuan over the past week, indicating significant growth [3] - The ETF's shares grew by 10 million shares this month, reflecting substantial growth [3] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 24.86, which is at a historical low, being in the 6.5% percentile over the past year [3] - A joint implementation plan for the digital transformation of the pharmaceutical industry has been issued by seven government departments, aiming for significant progress by 2027 [3] Group 3 - Short-term AI medical themes are expected to continue being a focus, with market attention shifting towards Q1 performance and potential improvements in the pharmaceutical industry by Q2 2025 [4] - The top ten weighted stocks in the Hang Seng Medical Index account for 57.69% of the index, including companies like BeiGene, WuXi Biologics, and JD Health [4] - Investors without stock accounts can access the Hang Seng Medical Index ETF through a linked fund for investment opportunities in the Hong Kong medical sector [4]

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...